CLOs on the Move

Gladden Longevity

www.gladdenlongevity.com

 
Gladden Longevity is a comprehensive concierge medical program dedicated to health optimization and performance, with a focus on age reversal. They offer wellness and fitness services, neurocognitive testing, body composition analysis, cardiovascular p...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Accessity

Accessity Corp. is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Westminster Gardens Health Ctr

Westminster Gardens Health Ctr is a Duarte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RoundGlass

RoundGlass is committed to enabling individuals to live their Journey of holistic Wellbeing and Meaningful Living™. The RoundGlass community of associates, portfolio companies, fellows, partners and ambassadors advocate and develop solutions across the RoundGlass holistic Wellbeing Pillars. The RoundGlass Wholistic Wellbeing Pillars: 1. Live – Wellbeing of self: From the right health care decision to celebrating life 2. Learn – Wellbeing of the future: Living with purpose and mastering key qualities 3. Give – Wellbeing of society: Empowering community wellbeing so that all members live with dignity 4. Sustain – Wellbeing of the planet: Meaningful programs that improve the environment

South Shore Hospital

South Shore Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. South Shore Hospital is based in South Weymouth, MA. You can find more information on South Shore Hospital at www.sshosp.org

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic